Multiplexed Protease Activity Assay Using Encoded Beads
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and characterizing active proteases are limited by their inability to simultaneously measure multiple activities, low throughput, high cost, insensitivity to endogenous inhibitors, and incompatibility with direct in situ measurements, which hinders the understanding of protease activity's influence on overall biological behavior and therapeutic efficacy.
Innovation Solution
The development of reagents and assays that use activity-based probes and encoded particles to sensitively and reliably measure active proteins in a multiplex manner, allowing for the identification and quantification of active proteases regardless of their activation state, using a low sample volume and enabling simultaneous detection of multiple analytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods (zymography, FRET-based polypeptide cleavage, activity-based ELISAs) are used to detect protease activity, then protease activity can be measured, but the throughput is low and the cost is high
Solution Approach 1:
The assay system segments the detection of multiple proteases by using encoded particles with unique identifiers for each protease type. Each encoded particle contains specific capture reagents that selectively bind to particular proteases, allowing parallel measurement of multiple proteases in separate but simultaneous assays. This segmentation enables high-throughput screening while maintaining specificity for each protease activity.
2Measurement precision
If conventional methods are used, then protease activity can be detected, but sensitivity to endogenous inhibitors is poor
Solution Approach 1:
The assay uses an intermediary activity-based probe that covalently binds to the active site of proteases. This probe acts as a mediator between the protease and the detection system, providing a direct measure of protease activity that is not affected by endogenous inhibitors. The probe's covalent binding ensures that only actively proteolytic enzymes are detected, eliminating interference from inhibitors that may bind to the same active site.
3Adaptability or versatility
If conventional methods are used, then protease activity can be measured, but they are incompatible with direct in situ measurements
Solution Approach 1:
The assay system achieves universality by designing encoded particles that can detect multiple proteases using a single standardized platform. The same basic assay format can measure different proteases by simply changing the encoded particle type, making the system adaptable to various proteolytic activities without requiring separate assay protocols for each protease. This multi-functionality enables both in vitro and in situ measurements using the same methodology.
4Quantity of substance
If conventional methods are used, then protease activity can be detected, but sample volume requirements are high
Solution Approach 1:
The assay employs parameter changes by using encoded particles with high-affinity capture reagents that significantly increase the detection sensitivity for proteases. This enhanced affinity allows the assay to detect proteases at much lower concentrations, thereby reducing the sample volume required from microliter to nanoliter scale while maintaining measurement precision through the high-specificity binding interactions.
Data Source
AI summary
Proteases regulate a wide range of normal cellular functions where dysregulated activity is observed in various diseases. Compositions and methods use protease activity multiplexed bead-based immunoassays to profile protease activity. This platform technology integrates protease activity measurements with total protein quantification techniques. It represents a significant improvement over existing detection techniques by allowing for multiplexed, sensitive active protease measurements in complex biological samples. Exemplary multiplexed detections are realized in a single assay using a minute sample amount (e.g., 5 μl) for active recombinant MMP-1, -2, -3, -7, 9, and 12 and those same MMPs in cell culture supernatant, menstrual fluid effluent, and peritoneal aspirates. This multiplexed platform achieves high level of sensitivities equal to or better than existing leading single-plex detection strategies. It also allows for high throughput screening to identify inhibitors of proteases in complex, donor-derived samples.